Spots Global Cancer Trial Database for progression
Every month we try and update this database with for progression cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression | NCT02443844 | Bladder Cancer | Transurethral R... Tamsulosin | 40 Years - 80 Years | Diskapi Teaching and Research Hospital | |
| Disease Progression and Treatment-induced Alterations in Glioblastoma | NCT02152748 | Brain Tumor | analyze systema... | - | Medical University of Vienna | |
| Prospective Sample Collection for Cancer of Bladder | NCT03973671 | Urinary Bladder... | 18 Years - 90 Years | Universitaire Ziekenhuizen KU Leuven | ||
| Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer | NCT04692675 | Prostate Cancer | mpMRI | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma | NCT04974671 | Renal Cell Carc... Metastatic Rena... Oligoprogressiv... Progression | Stereotactic Bo... | 18 Years - | Yale University | |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | NCT04503265 | Advanced Malign... Breast Cancer Ovarian Cancer Homologous Reco... Prostate Cancer Pancreatic Canc... | AMXI-5001:Dose ... AMXI-5001:Dose ... | 18 Years - | AtlasMedx, Incorporated | |
| Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III | NCT02761070 | Glioblastoma Recurrence Progression | Temozolomide Bevacizumab | 20 Years - 75 Years | Kyorin University | |
| Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer | NCT06235853 | Non-muscle Inva... Cystoscopy Recurrence Progression Bladder Cancer Biomarkers | Blood serum: sU... Urine: IL-8, AP... | 18 Years - | Wroclaw Medical University | |
| TRC105 for Recurrent Glioblastoma | NCT01778530 | Glioblastoma Mu... | TRC105 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III | NCT02761070 | Glioblastoma Recurrence Progression | Temozolomide Bevacizumab | 20 Years - 75 Years | Kyorin University | |
| Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma | NCT05532969 | Astrocytoma | stressors | 18 Years - 75 Years | Henan Provincial People's Hospital | |
| A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1 | NCT05184829 | Progression Postoperative R... | selective lymph... Systemic Lymph ... | 25 Years - 75 Years | Shanghai Zhongshan Hospital | |
| PD-L1 Expression in Advanced Osteosarcoma | NCT03582527 | Progression Survival | all study parti... | - | Peking University People's Hospital | |
| Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) | NCT02322320 | Multiple Myelom... | Lenalidomide | 18 Years - 70 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1 | NCT05184829 | Progression Postoperative R... | selective lymph... Systemic Lymph ... | 25 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT03121768 | Oncology Bladder Cancer Superficial Bla... Recurrence Progression BCG | 18 Years - | Mansoura University | ||
| A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | NCT04678648 | Advanced Malign... RAS Mutation Lung Cancer Colon Cancer Glioblastoma Pancreatic Canc... | RSC-1255 Dose E... RSC-1255 Dose E... | 18 Years - | RasCal Therapeutics, Inc. | |
| Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer | NCT01282931 | Metastatic Brea... | 18 Years - | Health Outcomes Solutions | ||
| Treatment of Recurrent GBM With APG-157 Via Expanded Access | NCT05551013 | Glioblastoma Glioblastoma Mu... | APG-157 | 18 Years - 85 Years | Aveta Biomics, Inc. | |
| Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma | NCT02715297 | Glioblastoma | SRT to the rese... | 18 Years - 99 Years | Technical University of Munich | |
| Understanding Communication in Healthcare to Achieve Trust (U-CHAT) | NCT02846038 | Brain Tumors Solid Tumor | - | St. Jude Children's Research Hospital | ||
| Laser Ablation After Stereotactic Radiosurgery | NCT01651078 | Metastatic Brai... Progression Radiation Necro... Quality of Life | 18 Years - | Monteris Medical | ||
| Combination of TATE and PD-1 Inhibitor in Liver Cancer | NCT03259867 | Hepatocellular ... Gastric Cancer | Nivolumab Injec... Trans-arterial ... | 18 Years - 80 Years | Teclison Ltd. | |
| Soluble B7-H3 as a Biomarker for Osteosarcoma | NCT05942456 | Biomarker Progression Osteosarcoma Surveillance | ELISA: enzyme-l... | 12 Years - | Peking University People's Hospital | |
| Combination of TATE and PD-1 Inhibitor in Liver Cancer | NCT03259867 | Hepatocellular ... Gastric Cancer | Nivolumab Injec... Trans-arterial ... | 18 Years - 80 Years | Teclison Ltd. | |
| The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression | NCT04617743 | Bladder Cancer ... Non-Invasive Bl... | 18 Years - | Istanbul Medeniyet University | ||
| Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma. | NCT04213664 | Renal Cell Carc... Progression Lymphocyte Diso... Monocytosis Local Disease | prognosis | 18 Years - | Corporacion Parc Tauli | |
| Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer | NCT06409416 | Lung Neoplasms Progression | Analysis of dia... | - | Casa Sollievo della Sofferenza IRCCS | |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | NCT05712356 | Cholangiocarcin... Gallbladder Can... Gallbladder Car... Intrahepatic Ch... Extrahepatic Ch... Bile Duct Cance... Gall Bladder Ca... Gall Bladder Ca... | LSTA1 Durvalumab Cisplatin Gemcitabine FOLFOX regimen Placebo | 18 Years - | Lisata Therapeutics, Inc. | |
| Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma | NCT00172367 | Carcinoma, Tran... | Lycopene | 18 Years - | National Taiwan University Hospital | |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | NCT05153330 | Acute Myeloid L... Acute Lymphobla... Acute Mixed-Phe... Cancer Refractory Progression Diffuse Large B... Multiple Myelom... Lymphoma Lymphoma, Non-H... Myeloma, Plasma... Myelomatosis Plasma Cell Mye... Chronic Lymphoc... Small Lymphocyt... | BMF-219 | 18 Years - | Biomea Fusion Inc. | |
| Bevacizumab and Irinotecan to Treat Brain Tumors | NCT00393094 | High-Grade Glio... | Bevacizumab Irinotecan hydr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer | NCT02321202 | Liver Cancer Cirrhosis | Omega-3 Fatty A... Structolipid | 18 Years - 75 Years | Huazhong University of Science and Technology | |
| Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC) | NCT01210131 | Small Cell Lung... | [18F]HX4 | 18 Years - | Maastricht Radiation Oncology | |
| Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma | NCT00172367 | Carcinoma, Tran... | Lycopene | 18 Years - | National Taiwan University Hospital | |
| Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients | NCT03541863 | Breast Cancer | - | Fudan University | ||
| Use of Circulating Exosomal LncRNA-GC1 to Monitor Gastric Cancer | NCT05397548 | Gastric Cancer | Measurement of ... | 18 Years - 80 Years | Chinese PLA General Hospital | |
| Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) | NCT01109004 | Multiple Myelom... | Lenalidomide lenalidomide, b... Lenalidomide | - 70 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| ZD6474 to Treat Advanced Brain Cancer in Patients | NCT00272350 | Recurrent High-... Progressive Low... Malignant Gliom... | Steroids ZD6474 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) | NCT01109004 | Multiple Myelom... | Lenalidomide lenalidomide, b... Lenalidomide | - 70 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Markers for Breast Cancer | NCT00339248 | Breast Cancer | 15 Years - | National Institutes of Health Clinical Center (CC) | ||
| Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) | NCT01109004 | Multiple Myelom... | Lenalidomide lenalidomide, b... Lenalidomide | - 70 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma | NCT04044378 | Effect of Drugs Progression Pediatric Cance... | Famitinib Ifosfamide Camrelizumab | 12 Years - | Peking University People's Hospital | |
| A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | NCT00995007 | Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... | ZD6474 (Vandeta... Carboplatin | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Prospective Collection of Samples for Urothelial Cancer of Bladder | NCT04167332 | Bladder Cancer | 18 Years - | Universitaire Ziekenhuizen KU Leuven | ||
| Bevacizumab and Irinotecan to Treat Brain Tumors | NCT00393094 | High-Grade Glio... | Bevacizumab Irinotecan hydr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT03121768 | Oncology Bladder Cancer Superficial Bla... Recurrence Progression BCG | 18 Years - | Mansoura University | ||
| Enzastaurin to Treat Recurrent Brain Tumor | NCT00108056 | Glioma | Enzastaurin (LY... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management | NCT02522585 | Cervical Cancer | Conservative ma... | 18 Years - | Parc de Salut Mar | |
| Understanding Communication in Healthcare to Achieve Trust (U-CHAT) | NCT02846038 | Brain Tumors Solid Tumor | - | St. Jude Children's Research Hospital | ||
| Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma. | NCT04213664 | Renal Cell Carc... Progression Lymphocyte Diso... Monocytosis Local Disease | prognosis | 18 Years - | Corporacion Parc Tauli | |
| A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules | NCT04905056 | Progression | Ablation therap... | 18 Years - 85 Years | Shanghai Zhongshan Hospital | |
| Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia | NCT03374332 | Acute Myeloid L... | Gemtuzumab Ozog... Donor Leukocyte... | 18 Years - | Brown University | |
| ZD6474 to Treat Advanced Brain Cancer in Patients | NCT00272350 | Recurrent High-... Progressive Low... Malignant Gliom... | Steroids ZD6474 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) | NCT02322320 | Multiple Myelom... | Lenalidomide | 18 Years - 70 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer | NCT06409416 | Lung Neoplasms Progression | Analysis of dia... | - | Casa Sollievo della Sofferenza IRCCS | |
| Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer | NCT00339651 | Endometrial Hyp... Endometrial Can... Postmenopausal ... Vaginal Bleedin... | 40 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer | NCT01980212 | Advanced Non-sm... First Line Trea... Thioredoxin Red... Carcinoembryoni... Progression | 18 Years - 80 Years | Hunan Province Tumor Hospital | ||
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | NCT05153330 | Acute Myeloid L... Acute Lymphobla... Acute Mixed-Phe... Cancer Refractory Progression Diffuse Large B... Multiple Myelom... Lymphoma Lymphoma, Non-H... Myeloma, Plasma... Myelomatosis Plasma Cell Mye... Chronic Lymphoc... Small Lymphocyt... | BMF-219 | 18 Years - | Biomea Fusion Inc. | |
| Treatment of Recurrent GBM With APG-157 Via Expanded Access | NCT05551013 | Glioblastoma Glioblastoma Mu... | APG-157 | 18 Years - 85 Years | Aveta Biomics, Inc. | |
| Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans | NCT03601624 | Multiple Myelom... Multiple Myelom... Refractory Mult... | Pomalidomide | 18 Years - | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | |
| Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers | NCT04723121 | Bladder Cancer | Urine ELISA for... Reverse transcr... | 18 Years - | Mansoura University | |
| Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression | NCT02443844 | Bladder Cancer | Transurethral R... Tamsulosin | 40 Years - 80 Years | Diskapi Teaching and Research Hospital | |
| Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients | NCT03541863 | Breast Cancer | - | Fudan University | ||
| Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer | NCT04692675 | Prostate Cancer | mpMRI | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| TRC105 for Recurrent Glioblastoma | NCT01778530 | Glioblastoma Mu... | TRC105 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD | NCT00908232 | Multiple Myelom... | Cyclophosphamid... Bortezomib Dexamethasone Lenalidomide | 18 Years - | Janssen-Cilag International NV | |
| Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer | NCT04300062 | Lung Cancer | Rebiopsy | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| ZD6474 to Treat Advanced Brain Cancer in Patients | NCT00272350 | Recurrent High-... Progressive Low... Malignant Gliom... | Steroids ZD6474 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients | NCT03541863 | Breast Cancer | - | Fudan University | ||
| Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer | NCT04300062 | Lung Cancer | Rebiopsy | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression | NCT04617743 | Bladder Cancer ... Non-Invasive Bl... | 18 Years - | Istanbul Medeniyet University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
